Sangamo Therapeutics (SGMO) Tops Q4 EPS by 8c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.26), $0.08 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $28 million versus the consensus estimate of $26.82 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• Deutsche Bank monitors UK auto sales as Chinese exports grow